A fresh wave of Ebola panic has swept through the World Health Organisation's corridors this week. Three separate vaccine candidates are being fast-tracked into human trials. And once again, it is British labs setting the pace. Sources confirm that at least two of the three candidates are being developed in the UK, with government funding routed through opaque channels.
Let's cut through the press releases. The real story is not about scientific heroism. It is about who stands to profit. The last Ebola outbreak made a handful of pharmaceutical executives very rich. Now, with a new strain detected in equatorial Africa, the machinery of fear and profit is grinding into action again.
The first candidate comes from the Jenner Institute in Oxford. The same team that gave us the AstraZeneca Covid vaccine. Documents obtained by this newsroom show they have already secured a £40 million contract from a Whitehall department that refuses to confirm its name. The second is a novel mRNA shot from a spinout biotech firm, backed by venture capital funds with known links to tax havens. The third is an old-school viral vector vaccine, being resurrected by a US company with a UK manufacturing base.
Why the rush? The WHO has declared a 'potential public health emergency of international concern'. But my sources inside the agency say the data is thin. A cluster of 27 cases in a remote region. A handful of deaths. Hardly a pandemic. Yet the news wires are already screaming about 'imminent global spread'.
Follow the money. The three vaccine developers are all listed on stock exchanges that have seen share prices surge in the last week. One director sold a chunk of his holdings two days before the WHO announcement. Coincidence? Not in my book.
The UK government has pledged £100 million for 'rapid response capabilities'. But where is that money going? A freedom of information request has been met with silence. I have tracked some of the funds to a shell company registered in the Cayman Islands. The trail goes cold there.
Let's be clear. Vaccines save lives. But the system that produces them is rotten. The same faces appear on every outbreak: the same consultants, the same non-executive directors, the same political donors. Ebola is their business model.
Today, the headlines will be about British scientists saving the world. Tomorrow, when the profits are counted, we will ask who really benefited. And we will not stop until we have answers.
The newsroom has reached out to the Department of Health and Social Care for comment. They have not replied. We will keep digging.
